logo: Foundation Medicine
icons
Poster and Presentations - June 2013

Saturday, June 1st, 2013

Poster Discussion

Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS)

June 1, 2013 @ 8:00 am – 12:00 pm

Location: E450b

Abstract /Poster #: 534

Collaborator: University of Chicago Medical Center

[View Abstract]

 

Poster Discussion

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

June 1, 2013 @ 8:00 am – 12:00 pm

Location: S102

Abstract /Poster #: 10514

Collaborator: Vanderbilt-Ingram Cancer Center

[View Abstract]

 

Poster Session

Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: analysis of associations with treatment on Phase I

June 1, 2013 @ 1:15 pm – 5:00 pm

Location: S Hall A2

Abstract /Poster #: 1051

Collaborator: MD Anderson Cancer Center

[View Abstract]

Oral Discussion

Next generation sequencing of genomic and cDNA identifies a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in spitz tumors

June 1, 2013 @ 2:00 pm – 2:15 pm

Location: 5406

Abstract /Poster #: 9002

[View Abstract]

 

Poster Session

Targeted next-generation sequencing of sarcomas for identification of therapeutic targets

June 1, 2013 @ 1:15 pm – 5:10 pm

Location: S Hall A2

Abstract /Poster #: 10577

Collaborator: MD Anderson Cancer Center

[View Abstract]

Sunday, June 2nd, 2013

Oral Discussion

An analysis of ERBB2 alterations (amplifications and mutations) found by next generations equencing (NGS) in 2000+ consecutive solid tumor (ST) patients

June 2, 2013 @ 8:00am – 8:15 am

Location: E354b

Abstract /Poster #: 11000

[View Abstract]

 

Poster Discussion

Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients

June 2, 2013 @ 8:00 am – 12:00 pm

Location: E450b

Abstract /Poster #: 8020

[View Abstract]

Poster Discussion

NTRK1 gene fusions represent a novel oncogene target in lung cancer

June 2, 2013 @ 8:00 am – 12:00 pm

Location: E450b

Abstract /Poster #: 8023

Collaborator: University of Colorado Denver School of Medicine

[View Abstract]

Monday, June 3rd, 2013

Poster Discussion

Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples

June 3, 2013 @ 8:00 am – 12:00 pm

Location: S102

Abstract /Poster #: 11020

[View Abstract]

 

Poster Discussion

Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer

June 3, 2013 @ 1:15 pm – 5:15 pm

Location: S102

Abstract /Poster #: 1009

[View Abstract]

Poster Session

Clinical next generation sequencing (NGS) of fine needle aspiration [FNA] biopsies in non-small cell lung (NSCLC) and pancreatic cancers

June 3, 2013 @ 1:15 pm – 5:15 pm

Location: S Hall A2

Abstract /Poster #: 11100

[View Abstract]

 

Poster Session

Frequency of MET amplification determined by comprehensive next generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors

June 3, 2013 @ 1:15 pm – 5:15 pm

Location: S Hall A2

Abstract /Poster #: 11068

[View Abstract]